Staar Surgical Company (STAA) Stock Price, Quote & News

Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, includin...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 626 303 7902

Fax: 626 359 8402

Website: www.staar.com

Address:

25510 Commercentre Drive, Lake Forest, United States

scalperD Jun. 24 at 6:05 PM

$STAA - 8-k filing out and 3.9 million new shares issued to insiders. Struck at $29.18. So let start to move up or entertain offers now that "incentive " is in place. Capitalism at its best.

1 · Reply

StockBraker Jun. 23 at 12:37 PM

$STAA Current COYPT is ~$33. STAAR is highly, almost symbiotically tied to the general macroeconomic recovery and consumer sentiment in China. While the company has made deliberate strategic efforts to diversify and expand—most notably in the U.S. market—China remains the single largest "swing factor" determining STAAR's overall corporate revenue and profitability. ICL procedures are highly discretionary, premium, and paid entirely out-of-pocket by consumers rather than via state insurance; however, STAAR's ICLs have found an exceptionally receptive market in China due to the country’s high rates of myopia (affecting over 700 million people).

0 · Reply

StockBraker Jun. 23 at 12:31 PM

$STAA STAAR Surgical director Richard T. LeBuhn received a new stock option grant as part of his director compensation. He was granted options covering 11,145 shares of common stock at an exercise price of $29.12 per share, with no cash paid for the grant. These options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. LeBuhn also holds previously granted options covering 7,524 shares at an exercise price of $18.46 per share that are currently exercisable and expire in 2036.

0 · Reply

imatisse Jun. 23 at 9:38 AM

BROADWOOD! Congrats BROADWOOD! Looks like $STAA is finally waking up from its coma.Mission partly accomplished! Surely the lesson with …must have been learned by now regarding how dangerous that low rate was. Now let’s talk $LCTX. The market is now pricing fear, not fundamentals… fear is in control. Fortunately, Mr. Market has a long history of changing his mind.

0 · Reply

jordann57 Jun. 13 at 4:52 PM

$STAA small cap flow improving, watch for follow-through if range flips

0 · Reply

stoks9 May. 29 at 9:26 PM

$STAA fd up stock but I like it

1 · Reply

stocksmit May. 28 at 7:46 PM

$STAA another odd dip on the day. I’m just buying a few every day 35 was not enough pre good China future outlook, so to me, 35 is a minimum here.

0 · Reply

Laynester May. 22 at 11:38 AM

$STAA TURNAROUND play. ON it! Not sure why Health care is a big deal really like the recent results tho. Long term indicators look great. All in on the L'ins (LENS) market. Set a stop good to all investors. 100%--->🦬

0 · Reply

stocksmit May. 20 at 3:43 PM

$STAA lol. Well, 70,000 share wall put up at 34 bucks so probably not gonna run over that I’d imagine

0 · Reply